IL224371A - 1– [2– (2,4-dimethyl-phenylsulfanyl) phenyl] piperazine for disease treatment - Google Patents

1– [2– (2,4-dimethyl-phenylsulfanyl) phenyl] piperazine for disease treatment

Info

Publication number
IL224371A
IL224371A IL224371A IL22437113A IL224371A IL 224371 A IL224371 A IL 224371A IL 224371 A IL224371 A IL 224371A IL 22437113 A IL22437113 A IL 22437113A IL 224371 A IL224371 A IL 224371A
Authority
IL
Israel
Prior art keywords
treatment
compound
patient
weight
disease
Prior art date
Application number
IL224371A
Other languages
English (en)
Hebrew (he)
Original Assignee
H Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL224371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck A/S filed Critical H Lundbeck A/S
Publication of IL224371A publication Critical patent/IL224371A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL224371A 2010-08-23 2011-08-22 1– [2– (2,4-dimethyl-phenylsulfanyl) phenyl] piperazine for disease treatment IL224371A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
IL224371A true IL224371A (en) 2016-07-31

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
IL224371A IL224371A (en) 2010-08-23 2011-08-22 1– [2– (2,4-dimethyl-phenylsulfanyl) phenyl] piperazine for disease treatment

Country Status (32)

Country Link
US (5) US20130184291A1 (enExample)
EP (1) EP2608789B2 (enExample)
JP (1) JP5902169B2 (enExample)
KR (1) KR101816953B1 (enExample)
CN (1) CN103068389A (enExample)
AP (1) AP3583A (enExample)
AR (1) AR082501A1 (enExample)
AU (1) AU2011295465B8 (enExample)
BR (2) BR122020025600A2 (enExample)
CA (1) CA2807062C (enExample)
CL (1) CL2013000492A1 (enExample)
CO (1) CO6680652A2 (enExample)
CY (1) CY1118886T1 (enExample)
DK (1) DK2608789T4 (enExample)
ES (1) ES2625142T5 (enExample)
FI (1) FI2608789T4 (enExample)
HR (1) HRP20170608T4 (enExample)
HU (1) HUE034155T2 (enExample)
IL (1) IL224371A (enExample)
LT (1) LT2608789T (enExample)
ME (1) ME02674B (enExample)
MX (1) MX349724B (enExample)
PL (1) PL2608789T5 (enExample)
PT (1) PT2608789T (enExample)
RS (1) RS55851B2 (enExample)
RU (1) RU2564666C2 (enExample)
SG (1) SG187649A1 (enExample)
SI (1) SI2608789T2 (enExample)
SM (1) SMT201700239T1 (enExample)
TW (1) TW201212918A (enExample)
WO (1) WO2012025123A1 (enExample)
ZA (1) ZA201301385B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
ES2087463T3 (es) * 1991-11-18 1996-07-16 Lilly Industries Ltd Benzo(b)tiofen-2-carboxamidas para el tratamiento de trastornos del sistema nervioso central.
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
WO2002029232A1 (en) 2000-10-02 2002-04-11 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
HUE034155T2 (en) 2018-01-29
BR122020025600A2 (pt) 2021-01-05
US20190000836A1 (en) 2019-01-03
KR20130097162A (ko) 2013-09-02
JP5902169B2 (ja) 2016-04-13
AU2011295465A1 (en) 2013-02-07
JP2013536206A (ja) 2013-09-19
RS55851B1 (sr) 2017-08-31
RU2013112890A (ru) 2014-09-27
SI2608789T2 (sl) 2025-05-30
RS55851B2 (sr) 2024-11-29
TW201212918A (en) 2012-04-01
PL2608789T5 (pl) 2025-11-12
HRP20170608T4 (hr) 2024-12-06
PT2608789T (pt) 2017-05-26
DK2608789T4 (da) 2024-11-04
US20220370439A1 (en) 2022-11-24
ES2625142T5 (en) 2025-02-10
LT2608789T (lt) 2017-05-25
ZA201301385B (en) 2014-04-30
AU2011295465B2 (en) 2014-06-19
CL2013000492A1 (es) 2013-06-07
MX2013001570A (es) 2013-03-21
RU2564666C2 (ru) 2015-10-10
WO2012025123A1 (en) 2012-03-01
KR101816953B1 (ko) 2018-01-09
PL2608789T3 (pl) 2017-09-29
CN103068389A (zh) 2013-04-24
EP2608789A1 (en) 2013-07-03
US20130184291A1 (en) 2013-07-18
EP2608789B2 (en) 2024-08-21
SI2608789T1 (sl) 2017-06-30
SG187649A1 (en) 2013-03-28
AP2013006768A0 (en) 2012-03-31
AP3583A (en) 2016-02-09
US20210085674A1 (en) 2021-03-25
DK2608789T3 (en) 2017-05-15
SMT201700239T1 (it) 2017-07-18
CO6680652A2 (es) 2013-05-31
AR082501A1 (es) 2012-12-12
ES2625142T3 (es) 2017-07-18
CY1118886T1 (el) 2018-01-10
FI2608789T4 (fi) 2024-11-01
MX349724B (es) 2017-08-10
HRP20170608T1 (hr) 2017-07-28
CA2807062C (en) 2018-07-31
AU2011295465B8 (en) 2014-07-10
CA2807062A1 (en) 2012-03-01
US20240293397A1 (en) 2024-09-05
EP2608789B1 (en) 2017-04-12
ME02674B (me) 2017-06-20
BR112013002194A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
US20240293397A1 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
Outfitters et al. Revisiting monoamine oxidase inhibitors
US20020099045A1 (en) Combination treatment for depression
JP2004517112A (ja) 新規薬物コンビネーション
EP2523557B1 (en) Methods of providing weight loss therapy in patients with major depression
TW202317101A (zh) 治療抑鬱狀態之方法
EP0759299A1 (en) Potentiation of serotonin response
RS67696B1 (sr) Vafidemstat za lečenje neagresivnih simptoma graničnog poremećaja ličnosti
HK1184374A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
AU2021404187A9 (en) Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders
CN114080221B (zh) 用于减轻疼痛的布洛芬与曲马多的组合
US20030212109A1 (en) Pharmaceutical compositions and their use
KR20140069120A (ko) S1p 수용체 조절제를 포함하는 조합물
JP2007533699A (ja) 医薬
JPWO2007034910A1 (ja) 過食症及び過食症に伴ううつ病の治療用医薬組成物

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed